AU2001281071A1 - Ammonium salts of hemoglobin allosteric effectors, and uses thereof - Google Patents

Ammonium salts of hemoglobin allosteric effectors, and uses thereof

Info

Publication number
AU2001281071A1
AU2001281071A1 AU2001281071A AU8107101A AU2001281071A1 AU 2001281071 A1 AU2001281071 A1 AU 2001281071A1 AU 2001281071 A AU2001281071 A AU 2001281071A AU 8107101 A AU8107101 A AU 8107101A AU 2001281071 A1 AU2001281071 A1 AU 2001281071A1
Authority
AU
Australia
Prior art keywords
ammonium salts
allosteric effectors
hemoglobin
hemoglobin allosteric
effectors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001281071A
Inventor
Dennis R. Alford
Jaime E Lazarte
Yves Claude Nicolau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GMP COMPANIES Inc
Original Assignee
GMP Cos Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GMP Cos Inc filed Critical GMP Cos Inc
Publication of AU2001281071A1 publication Critical patent/AU2001281071A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/093—Polyol derivatives esterified at least twice by phosphoric acid groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2001281071A 2000-08-01 2001-08-01 Ammonium salts of hemoglobin allosteric effectors, and uses thereof Abandoned AU2001281071A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22206600P 2000-08-01 2000-08-01
US60/222,066 2000-08-01
PCT/US2001/024514 WO2002009723A2 (en) 2000-08-01 2001-08-01 Ammonium salts of hemoglobin allosteric effectors, and uses thereof

Publications (1)

Publication Number Publication Date
AU2001281071A1 true AU2001281071A1 (en) 2002-02-13

Family

ID=22830663

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001281071A Abandoned AU2001281071A1 (en) 2000-08-01 2001-08-01 Ammonium salts of hemoglobin allosteric effectors, and uses thereof

Country Status (3)

Country Link
US (1) US20020142995A1 (en)
AU (1) AU2001281071A1 (en)
WO (1) WO2002009723A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2828206B1 (en) * 2001-08-03 2004-09-24 Centre Nat Rech Scient USE OF LYSYL OXIDASE INHIBITORS FOR CELL CULTURE AND TISSUE ENGINEERING
AU2003231157C1 (en) 2002-04-29 2009-02-26 Normoxys, Inc. Inositol pyrophosphates, and methods of use thereof
US7745423B2 (en) * 2004-07-06 2010-06-29 NormOxys, Inc Calcium/sodium salt of inositol tripyrophosphate as an allosteric effector of hemoglobin
US20060106000A1 (en) * 2004-07-06 2006-05-18 Claude Nicolau Use of inositol-tripyrophosphate in treating tumors and diseases
US20060258626A1 (en) * 2004-07-06 2006-11-16 Claude Nicolau Use of inositol-tripyrophosphate in treating tumors and diseases
EP1863495B1 (en) * 2005-03-18 2015-02-18 NormOxys, Inc. Calcium and sodium salt of myo-inositol 1,6:2,3:4,5 tripyrophosphate for treating cancer
AU2008246061A1 (en) * 2007-05-01 2008-11-06 Normoxys, Inc. Erythropoietin complementation or replacement
HUE035069T2 (en) 2011-12-28 2018-05-02 Global Blood Therapeutics Inc Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
WO2013102145A1 (en) 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
KR20150132146A (en) 2013-03-15 2015-11-25 글로벌 블러드 테라퓨틱스, 인크. Compounds and uses thereof for the modulation of hemoglobin
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
CA2903022C (en) 2013-03-15 2021-11-09 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
PE20161035A1 (en) 2013-03-15 2016-11-13 Global Blood Therapeutics Inc COMPOUNDS AND USES OF THESE FOR THE MODULATION OF HEMOGLOBIN
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
EA201992707A1 (en) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. COMPOUNDS AND THEIR APPLICATIONS FOR HEMOGLOBIN MODULATION
JP6809681B2 (en) 2014-02-07 2021-01-06 グローバル ブラッド セラピューティクス インコーポレイテッド Crystal polymorphism of the free base of 2-hydroxy-6-((2- (1-isopropyl-1H-pyrazole-5-yl) pyridin-3-yl) methoxy) benzaldehyde
MA41841A (en) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc ALDEHYDE COMPOUNDS FOR THE TREATMENT OF PULMONARY FIBROSIS, HYPOXIA, AND AUTOIMMUNE AND CONNECTIVE TISSUE DISEASES
TW201731509A (en) 2015-12-04 2017-09-16 全球血液治療公司 Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
TWI663160B (en) 2016-05-12 2019-06-21 全球血液治療公司 Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
TW202332423A (en) 2016-10-12 2023-08-16 美商全球血液治療公司 Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
EP3860975B1 (en) 2018-10-01 2023-10-18 Global Blood Therapeutics, Inc. Modulators of hemoglobin for the treatment of sickle cell disease
EP3917535A1 (en) * 2019-01-30 2021-12-08 Sanifit Therapeutics S.A. Inositol phosphate compounds for use in increasing tissular perfusion

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3847738A (en) * 1971-11-01 1974-11-12 American Hospital Supply Corp Blood collection and preservation unit
JPS5826916B2 (en) * 1980-01-22 1983-06-06 日本新薬株式会社 Manufacturing method of diphosphoglycerate
US5039665A (en) * 1980-07-21 1991-08-13 Markov Angel K Use of fructose-1,6-diphosphate for treating myocardial infarction
US4546095A (en) * 1980-07-21 1985-10-08 Markov Angel K Use of fructose-1,6-diphosphate for treating myocardial infarction
US4397846A (en) * 1981-05-15 1983-08-09 Murray Weiner Storage-stable lipid vesicles and method of preparation
US4757052A (en) * 1982-09-03 1988-07-12 Markov Angel K Method of preserving blood
US4887995A (en) * 1985-01-22 1989-12-19 University Of Pittsburgh Method of treating sickle cell anemia
US4669926A (en) * 1986-01-21 1987-06-02 Wilcox Jr Robert D Drill guide apparatus and method
GB8606913D0 (en) * 1986-03-20 1986-04-23 Hider R C Treatment of sickle cell disease
US4751244A (en) * 1986-04-04 1988-06-14 Merck & Co., Inc. Compounds useful in treating sickle cell anemia
US4731473A (en) * 1986-04-04 1988-03-15 Merck & Co., Inc. Compounds useful in treating sickle cell anemia
US4731381A (en) * 1986-04-04 1988-03-15 Merck & Co., Inc. Method of treating a person for sickle cell anemia
JPH01294631A (en) * 1988-05-19 1989-11-28 Sanwa Kagaku Kenkyusho Co Ltd Remedy and preventive for diabetic disease, food and drink and table luxury
US5211956A (en) * 1988-05-19 1993-05-18 Sanwa Kagaku Kenkyusho Co., Ltd. Pharmaceutical compositions containing phytic acid or its salts
US5041429A (en) * 1988-06-01 1991-08-20 Sanwa Kagaku Kenkyusho Co., Ltd. Cell activators, circulatory ameliorators and edible compositions
US4861795A (en) * 1988-06-23 1989-08-29 Rorer Pharmaceutical Corporation Treatment of conditions requiring enhanced oxygen availability to mammalian tissues
US5015663A (en) * 1988-06-23 1991-05-14 Rhone-Poulenc Rorer Pharmaceuticals Inc. Treatment of conditions requiring enhanced oxygen availability of mammalian tissues
US4948582A (en) * 1988-06-23 1990-08-14 Rorer Pharmaceutical Corporation Treatment of conditions requiring enhanced oxygen availability to mammalian tissues
JPH0215032A (en) * 1988-07-01 1990-01-18 Sanwa Kagaku Kenkyusho Co Ltd Remedy and preventive for liver disease and drink and favorite food having strong liver functionality
US4849416A (en) * 1988-07-25 1989-07-18 Rorer Pharmaceutical Corporation Treatment of conditions requiring enhanced oxygen availability to mammalian tissues
DE3925680A1 (en) * 1989-08-03 1991-02-07 Kruess Gmbh Wissenschaftliche PROCESS FOR PRODUCING VITAL ACTIVE-LOADED HUMANERYTHROCYTES
US5173426A (en) * 1989-10-06 1992-12-22 Yale University DNAs encoding genetically engineered low oxygen affinity mutants of human hemoglobin
JP3185108B2 (en) * 1990-11-07 2001-07-09 バクスター、インターナショナル、インコーポレイテッド Erythrocyte storage solution
US5296466A (en) * 1992-02-19 1994-03-22 Board Of Regents, The University Of Texas System Inhibition of nitric oxide-mediated hypotension and septic shock with iron-containing hemoprotein
US5344393A (en) * 1992-02-28 1994-09-06 Alliance Pharmaceutical Corp. Use of synthetic oxygen carriers to facilitate oxygen delivery
DE69433933T2 (en) * 1993-03-23 2005-07-21 CBR Laboratories, Inc., Boston METHOD AND DEVICE FOR INCLUSION OF BIOLOGICALLY ACTIVE SUBSTANCES IN CELLS
WO2002010177A1 (en) * 2000-08-01 2002-02-07 Gmp Companies, Inc. Ammonium salts of inositol hexaphosphate and uses thereof

Also Published As

Publication number Publication date
WO2002009723A3 (en) 2003-07-17
WO2002009723A2 (en) 2002-02-07
US20020142995A1 (en) 2002-10-03

Similar Documents

Publication Publication Date Title
AU2001281071A1 (en) Ammonium salts of hemoglobin allosteric effectors, and uses thereof
AU2002317910A1 (en) Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof
AU2001251205A1 (en) Multiple bias surgical fastener
AU2002245479A1 (en) Coformulation of carfentrazone-ethyl and glyphosate
AU2002367186A1 (en) Urea derivatives
AU2002359633A1 (en) Nox, hg, and so2 removal using ammonia
HUP0401335A3 (en) Herbicidal pyridylpropynyloxyphenyl derivatives, preparation and use thereof
IL161885A0 (en) Sulphonamide derivatives, the preparation thereof and the application of same as medicaments
AU2002359126A1 (en) Benzodiazepine derivatives, preparation thereof and use thereof
AU2001279118A1 (en) Ammonium salts of inositol hexaphosphate and uses thereof
AU2002359123A1 (en) Benzodiazepine derivatives, preparation thereof and use thereof
AU2208401A (en) Inhibitors of complement activation, their preparation and use
AU2001258305A1 (en) Salts of bicyclic, N-acylated imidazo-3-amines and imidazo-5-amines
AU3565199A (en) Catalytic composition comprising a titanium compound, an amine and a phosphorus compound; preparation and use thereof
AU2002214948A1 (en) Heterocyclylalkyl azole derivatives and use thereof as pesticidal agents
AU2001267645A1 (en) Cyclic urea compounds and preparation thereof
AU2002333373A1 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
AUPR000100A0 (en) Ammonia storage
AU5029801A (en) Copolymers of allylphosphonium salts
IL139731A0 (en) N-acetyl 3-chloropocainamide, acid addition salts thereof, and methods of use
AU2001232075A1 (en) Compound, composition and use
AU2003239973A1 (en) Sterols bearing pendant allosteric effectors of hemoglobin, and uses thereof
AU2001284084A1 (en) Polyfluoroalkyltriazole derivatives, preparation and therapeutic use thereof
AU2003303019A1 (en) Water-soluble clathrates of ziprasidone and its salts, and the preparation methods therefor
ZA200508358B (en) Pharmaceutically active ornithine derivatives, ammonium salts thereof and methods of making same